natgillin/translations-raw huggingface dataset:
Therecommendeddose is one tablet by mouth daily.Taking more than one tablet daily is not more effective and may carry additional risks. 
Če vzamete več kot eno tableto na dan učinkovitost ne bo večja, lahko pa je to povezano z dodatnimi tveganji.
When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1). 
Pri odločanju za zdravljenje z zdravilom CONBRIZA ali drugimi zdravili, vključno z estrogeni, je treba upoštevati simptome menopavze, delovanje na tkiva maternice in dojk in kardiovaskularna tveganja in koristi (glejte poglavje 5.1) pri posamezni ženski v postmenopavzi posebej.
Each film-coated tablet contains bazedoxifene acetate equivalent to 20 mg bazedoxifene. 
Ena filmsko obložena tableta vsebuje bazedoksifenijev acetat v količini, ki ustreza 20 mg bazedoksifena.
In a 30-day study, bazedoxifene increased hormone-binding globulin concentrations, including corticosteroid-binding globulin (CBG), sex hormone-binding globulin (SHBG) and thyroxine-binding globulin (TBG). 
V 30-dnevni študiji je bazedoksifen zvišal koncentracije globulinov, ki vežejo hormone, med drugim globulina, ki veže kortikosteroide (CBG), globulina, ki veže spolne hormone (SHBG), in globulina, ki veže tiroksin (TBG).
Bazedoxifene must not be taken by women of child-bearing potential (see sections 4.6 and 5.3). 
Ženske v rodni dobi bazedoksifena ne smejo jemati (glejte poglavji 4.6 in 5.3).
The other ingredients are lactose monohydrate (see section 2 “CONBRIZA contains lactose”), microcrystalline cellulose, pre-gelatinised starch (maize), sodium starch glycolate, sodium lauryl sulfate, colloidal anhydrous silica, magnesium stearate, ascorbic acid, hypromellose, titanium dioxide (E171) and macrogol 400. 
- Druge sestavine zdravila so laktoza monohidrat (glejte poglavje 2 ''Zdravilo CONBRIZA vsebuje laktozo''), mikrokristalna celuloza, predgelirani škrob (koruzni), natrijev karboksimetilškrob, natrijev lavrilsulfat, koloidni brezvodni silicijev dioksid, magnezijev stearat, askorbinska kislina, hipromeloza, titanov dioksid (E171) in makrogol 400.
Cerebrovascular effects 
Možganskožilni učinki
It is contraindicated in women of child-bearing potential (see section 4.3). 
Kontraindicirano je pri ženskah v rodni dobi (glejte poglavje 4.3).
The effects of bazedoxifene treatment on bone, uterus, and mammary gland were assessed in ovariectomized rats (0.15 to 1.5 mg/kg/day) and non-human primates [Cynomolgus macaques] (0.2 to 25.0 mg/kg/day). 
Učinki dajanja bazedoksifena na kosti, maternico in mlečne žleze so ocenjevali pri ovariektomiranih podganah (odmerki 0,15 do 1,5 mg/kg/dan) in nehumanih primatih [Cynomolgus macaques] (0,2 do 25,0 mg/kg/dan).
Use of CONBRIZA is not recommended in women at an increased risk for venous thromboembolic events. 
Uporaba zdravila CONBRIZA ni priporočljiva pri ženskah z zvečanim tveganjem venskih trombemboličnih dogodkov.
Safety and efficacy have not been evaluated further in patients with hepatic insufficiency. 
Pri bolnicah z insuficienco jeter varnosti in učinkovitosti niso natančneje ovrednotili.
The partial preservation of bone mass was achieved by reductions in the ovariectomy-induced increases in bone turnover, evaluated by biochemical markers of bone turnover and histomorphometric indices measured in cancellous and cortical bone. 
Delna ohranitev kostne mase je bila dosežena z zmanjšanjem zvečanja premene kostnine, povzročenega z ovariektomijo, vrednotenega z biokemijskimi označevalci premene kostnine in histomorfometrijskimi indeksi, izmerjenimi v retikularni in kortikalni kosti.
Bazedoxifene was not genotoxic or mutagenic in a battery of tests, including in vitro bacterial reverse mutation assay, in vitro mammalian cell forward mutation assay at the thymidine kinase (TK±) locus in L5178Y mouse lymphoma cells, in vitro chromosome aberration assay in Chinese hamster ovary (CHO) cells, and in vivo mouse micronucleus assay. 
Bazedoksifen ni bil genotoksičen ali mutagen v seriji testov, med drugim pri in vitro bakterijskem testu reverznih mutacij, in vitro testu naprednih mutacij v sesalskih celicah na lokusu timidinske kinaze (TK±) v celicah mišjega limfoma L5178Y, in vitro testu kromosomskih aberacij v ovarijskih celicah kitajskega hrčka (CHO) in in vivo mikronukleusnem testu pri miših.
In clinical trials, the highest rate of VTE was observed during the first year of treatment, with a relative risk of 2.69 compared to placebo. 
V kliničnih preskušanjih so največji delež VTE opažali v prvem letu zdravljenja, pri čemer je relativno tveganje v primerjavi s placebom znašalo 2,69.
This study included mostly Caucasian (87.3%) subjects who were either osteoporotic without baseline vertebral fracture (BMD T-score at lumbar spine [LS] or femoral neck [FN] between -2.5 and -4.0) or osteoporotic, with at least 1 mild baseline vertebral fracture. 
V to študijo so bile vključene večinoma belke (87,3 %), ki so bodisi imele osteoporozo brez izhodiščnega zloma vretenc (ocena T na lestvici MKG na ledveni hrbtenici [LS] ali stegneničnem vratu [FN] med -2,5 in -4,0), bodisi so imele osteoporozo z vsaj enim blagim izhodiščnim zlomom vretenc.
The effect of bazedoxifene on BMD at other skeletal sites was similar. 
Učinek bazedoksifena na MKG na drugih mestih v skeletu je bil podoben.
Very common(may affect more than 1 in 10 people): 
Zelo pogosti(pojavijo se lahko pri več kot 1 od 10 bolnic):
In subjects with a fracture probability of 20% or greater (n = 618), the risk of non-vertebral fractures in bazedoxifene-treated subjects was decreased by 55% (95% CI: 18-76) compared to placebo-treated subjects. 
Pri osebah z verjetnostjo zloma 20 % ali več (n = 618) se je nevarnost nevretenčnih zlomov pri osebah, zdravljenih z bazedoksifenom, v primerjavi z osebami, ki so prejemale placebo, zmanjšala za 55 % (95 % IZ: 18-76).
CONBRIZA is associated with an increased risk of venous thromboembolism (VTE). 
Zdravilo CONBRIZA je povezano s povečanim tveganjem za pojav venske trombembolije (VTE).
Bazedoxifene acts as both an oestrogen-receptor agonist and/or antagonist, depending upon the cell and tissue type and target genes. 
Bazedoksifen deluje kot oboje, agonist ali antagonist estrogenskih receptorjev, odvisno od vrste celic in tkiva in pa tarčnih genov.
Repeated-dose studies in normally cycling rodents and cynomolgus monkeys revealed a marked stimulation of ovarian follicle growth without ovulation, leading to partly haemorrhagic-ovarian cysts and markedly elevated estradiol levels. 
Študije ponavljajočih se odmerkov pri glodalcih in opicah cinomolgus z normalnim ciklom so pokazale izrazito spodbujanje rasti ovarijskih foliklov brez ovulacije, kar povzroči nastanek delno hemoragičnih ovarijskih cist in izrazito zvišano koncentracijo estradiola.
No data are available on the concomitant use with agents used in the treatment of early or advanced breast cancer. 
O sočasni uporabi z zdravili, ki se uporabljajo za zdravljenje zgodnjega ali napredovalega raka dojk, podatkov ni na voljo.
Safety and efficacy of bazedoxifene have not been evaluated in patients with hepatic impairment; use in this population is not recommended (see sections 4.4 and 5.2). 
Pri bolnicah z okvaro jeter varnosti in učinkovitosti bazedoksifena niso ovrednotili; uporaba zdravila pri tej skupini bolnic ni priporočljiva (glejte poglavji 4.4 in 5.2).
The observation of benign, ovarian granulosa-cell tumours in female mice and rats administered bazedoxifene is a class effect of SERMs, related to its pharmacology in rodents when treated during their reproductive lives, when their ovaries are functional and responsive to hormonal stimulation. 
Opaženi benigni ovarijski granulozocelularni tumorji pri mišjih in podganjih samicah, ki so prejemale bazedoksifen, je učinek skupine SERM, ki je povezan z njihovo farmakologijo pri samicah glodalcev, ki jih prejemajo v reproduktivni dobi, ko so njihovi jajčniki funkcionalni in se odzivajo na hormonsko stimulacijo.
Effects on the breast 
Učinki na maternico
Negligible amounts of bazedoxifene were eliminated in urine. 
Z urinom se je izločila zanemarljiva količina bazedoksifena.
if you have any vaginal bleeding while you take CONBRIZA, you should speak with your doctor. 
če med jemanjem zdravila CONBRIZA začnete krvaveti iz nožnice, se morate pogovoriti z zdravnikom.
White to off-white, capsule-shaped, film-coated tablet debossed on one side with “WY20”. 
Bela do sivobela, po obliki kapsuli podobna filmsko obložena tableta z napisom “WY20”, vtisnjenim na eni strani.
Bazedoxifene functions primarily as an oestrogen-receptor antagonist in uterine and breast tissues. 
Bazedoksifen deluje primarno kot antagonist estrogenskih receptorjev v tkivih maternice in dojk.
In vitro data suggest that bazedoxifene is unlikely to interact with co-administered medicinal products via CYP-mediated metabolism. 
Podatki in vitro kažejo, da je malo verjetno, da bazedoksifen medsebojno deluje s sočasno danimi zdravili preko presnove, ki jo uravnava CYP.
CONBRIZA has only been studied in women who have reached menopause, and therefore is not recommended. 
Zdravilo CONBRIZA so raziskovali le pri ženskah, ki so dosegle menopavzo, zato ga pri ženskah pred menopavzo ne priporočamo.
Additionally, uterine wet weights were reduced compared with untreated animals and histologic evaluation demonstrated little to no difference from the untreated controls. 
Poleg tega je bila vlažna teža maternice v primerjavi z živalmi, ki niso prejemale bazedoksifena, zmanjšana, histološki pregled pa je pokazal malo ali nič razlik med njimi in kontrolno skupino.
The disposition of a single 20 mg dose of bazedoxifene was compared in patients with hepatic impairment [Child-Pugh Class A (n=6), B (n=6), and C (n=6)] and subjects with normal hepatic function (n=18). 
Primerjali so presnovo enkratnega 20 mg odmerka bazedoksifena pri bolnicah z okvaro jeter [razredi A (n = 6), B (n = 6) in C (n = 6) po Child-Pughovi lestvici] in bolnicah z normalnim delovanjem jeter (n = 18).
If you stop taking CONBRIZA 
Če ste prenehali uporabljati zdravilo CONBRIZA
What CONBRIZA looks like and contents of the pack 
Izgled zdravila CONBRIZA in vsebina pakiranja
Patients with hepatic impairment showed a 4.3-fold increase in area under the curve (AUC) [on average] compared with controls. 
Bolnice z okvarami jeter so v primerjavi s kontrolno skupino pokazale 4,3-kratno zvečanje površine pod krivuljo (AUC) [povprečno].
CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. 
Zdravilo CONBRIZA je indicirano za zdravljenje postmenopavzalne osteoporoze pri ženskah z zvečanim tveganjem zlomov.
In the breast-density study, an ancillary study of the osteoporosis treatment study, 444 postmenopausal women (mean age = 59 years) with osteoporosis from all 4 treatment groups, were evaluated for mammographic breast density changes at 24 months. 
V študiji preverjanja gostote dojk, stranski študiji ob študiji zdravljenja osteoporoze, je bilo ocenjenih 444 žensk v obdobju po menopavzi (povprečna starost = 59 let) z osteoporozo iz vseh 4 skupin zdravljenja, glede na spremembe v mamografski gostoti dojk po 24 mesecih.
Subjects with no baseline fracture n=757 
Osebe brez izhodiščnih zlomov n = 757
On average, patients with hepatic impairment showed a 4.3-fold increase in AUC compared with controls. 
Bolnice z okvaro jeter so v primerjavi s kontrolno skupino pokazale v povprečju 4,3-kratno zvečanje AUC.
Blood triglycerides increased, alanine aminotransferase increased, aspartate aminotransferase increased. 
Preiskave zvišani trigliceridi v krvi, zvišana alaninaminotransferaza, zvišana aspartataminotransferaza
On average, compared to women 51 to 64 years of age (n=8), women 65 to 74 years of age (n=8) showed a 1.5-fold increase in AUC, and women 75 years of age (n=8) showed a 2.3-fold increase in AUC. 
V primerjavi z ženskami, starimi 51 do 64 let (n = 8), so imele ženske, stare 65 do 74 let (n = 8), 1,5-krat večjo AUC, ženske, stare  75 let (n = 8), pa 2,3-krat večjo AUC.
If you take more CONBRIZA than you should 
Če ste vzeli večji odmerek zdravila CONBRIZA, kot bi smeli
The effect on triglycerides in the bazedoxifene 20 mg and raloxifene 60 mg groups was similar to placebo. 
Učinek na trigliceride v skupinah z bazedoksifenom v odmerku 20 mg in raloksifenom v odmerku 60 mg je bil podoben učinku placeba.
After 7 years of treatment with bazedoxifene the increases in BMD relative to placebo remained statistically significant at the femoral neck, femoral trochanter, and total hip. 
Po sedmih letih zdravljenja z bazedoksifenom so povečanja MKG v primerjavi s placebom ostala statistično pomembna za stegnenični vrat, stegnenični trohanter in celoten kolk.
Subjects with 1 baseline fracture n=967 
Osebe z ≥ 1 izhodiščnim zlomom n = 967
Like the rodent results, bazedoxifene treatment in non-human primates resulted in uterine and mammary gland atrophy without other histological differentiation from untreated animals. 
Podobno kot pri glodalcih je dajanje bazedoksifena nehumanim primatom povzročilo atrofijo maternice in mlečnih žlez brez drugih histoloških razlik v primerjavi z živalmi, ki niso prejemale bazedoksifena.
Paediatric population There is no relevant use of bazedoxifene in the paediatric population. 
Pediatrična populacija Bazedoksifen ni primeren za uporabo pri pediatrični populaciji.
It may increase serum triglyceride levels; therefore, caution should be exercised in patients with known hypertriglyceridaemia (see section 5.1). 
Ker bazedoksifen lahko zviša koncentracijo trigliceridov v serumu, je pri bolnicah z znano hipertrigliceridemijo potrebna previdnost (glejte poglavje 5.1).
Systemic exposure (AUC) of bazedoxifene in these groups was 2.6 and 6.6 times that observed in postmenopausal women administered 20 mg/day for 14 days. 
Sistemska izpostavljenost (AUC) bazedoksifenu v teh skupinah je bila 2,6-krat oziroma 6,6-krat večja kot pri ženskah v postmenopavzi, ki so 14 dni prejemale po 20 mg/kg/dan.
The underlying nature of these events is uncertain. 
Vzrok teh učinkov ni natančno znan.
Treatment of rats at maternally toxic doses 1 mg/kg/day (0.3 times the human exposure) resulted in reduced numbers of live foetuses and/or reductions in foetal body weights. 
Odmerki  1 mg/kg/dan ( 0,3-kratna izpostavljenost pri človeku) so pri podganah povzročili zmanjšano število živih plodov in/ali zmanjšanje njihove telesne mase.
The increases in BMD relative to placebo remained statistically significant at all skeletal sites throughout the 5 years of treatment with bazedoxifene. 
Povečanja MKG v primerjavi s placebom so v petih letih zdravljenja z bazedoksifenom ostala statistično pomembna na vseh mestih v skeletu.
Paediatric population The pharmacokinetics of bazedoxifene have not been studied in the paediatric population. 
Pediatrična populacija Pri pediatrični populaciji farmakokinetike bazedoksifena niso proučevali.
Systemic exposure (AUC) to bazedoxifene in these groups was 35 and 69 times that in postmenopausal women administered 20 mg/day for 14 days. 
Sistemska izpostavljenost (AUC) bazedoksifenu pri teh skupinah je bila 35-krat oziroma 69-krat večja kot pri ženskah v postmenopavzi, ki so 14 dni dobivale po 20 mg/dan.
These reports include visual acuity reduced, blurred vision, photopsia, visual field defect, visual impairment, dry eye, eyelid oedema, blepharospasm, eye pain and eye swelling. 
Ta poročila vključujejo zmanjšanje ostrine vida, zamegljen vid, fotopsijo, izpad vidnega polja, okvaro vida, suhe oči, edem očesne veke, blefarospazem, bolečine v očesu in otekanje očesa.
If ocular symptoms occur, patients should be advised to seek medical attention. 
Če se očesni neželeni učinki pojavijo, naj bolnica poišče medicinsko pomoč.
Median reductions from baseline over 25% for C-telopeptide and osteocalcin were observed with bazedoxifene therapy. 
Pri zdravljenju z bazedoksifenom so ugotovili mediano znižanje C-telopeptida in osteokalcina od izhodišča za več kot 25 %.
Female rats were administered daily doses of 0.3 to 30 mg/kg (0.03 to 8 times the human exposure) prior to and during mating with untreated males. 
Podganje samice so prejemale dnevne odmerke od 0,3 do 30 mg/kg na dan (0,03- do 8-kratnik izpostavljenosti pri človeku) pred parjenjem s samci, ki niso prejeli zdravila, in po njem.
Such discontinuation was statistically significant more frequently in the placebo group (4.0%) than in the bazedoxifene 20 mg (2.8%) or raloxifene 60 mg (2.1%) groups. 
Taka izključitev je bila pogosteje statistično pomembna v skupini s placebom (4,0 %) kot v skupini z bazedoksifenom v odmerku 20 mg (2,8 %) ali raloksifenom v odmerku 60 mg (2,1 %).
Active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. 
Sedanja ali pretekla anamneza venskih trombemboličnih dogodkov, vključno z globoko vensko trombozo, pljučno embolijo in trombozo ven mrežnice.
The incidence of non-vertebral osteoporosis-related fractures was similar among bazedoxifene 20 mg (5.68%), raloxifene 60 mg (5.87%), and placebo (6.26%) groups. 
Pojavnost nevretenčnih zlomov, povezanih z osteoporozo, je bila v skupinah, ki so prejemale bazedoksifen v odmerku 20 mg (5,68 %), raloksifen v odmerku 60 mg (5,87 %) in placebo (6,26 %), podobna.
Unexplained uterine bleeding. 
Nepojasnjena maternična krvavitev.
Bazedoxifene belongs to a class of compounds known as selective estrogen receptor modulators (SERMs). 
Bazedoksifen spada v skupino selektivnih modulatorjev estrogenskih receptorjev (SERM).
Deep vein thrombosis*, thrombophlebitis superficial 
Žilne bolezni vročinski oblivi globoka venska tromboza*, površinski tromboflebitis
Bazedoxifene has not been studied in women with triglyceride levels 300 mg/dl (3.4 mmol/litre). 
Pri ženskah s koncentracijo trigliceridov  300 mg/dl ( 3,4 mmol/liter) bazedoksifena niso proučevali.
CONBRIZA is supplied as a white to off-white, capsule-shaped, film-coated tablet marked with “WY20”. 
Zdravilo CONBRIZA je na voljo v obliki belih do sivobelih, po obliki kapsuli podobnih filmsko obloženih tablet z napisom “WY20”.
The reduction in the incidence of vertebral fracture was similar among bazedoxifene and raloxifene treatment groups. 
Zmanjšanje incidence zlomov vretenc je bilo v skupinah, zdravljenih z bazedoksifenom in raloksifenom, podobno.
Bazedoxifene is rapidly absorbed with a tmax of approximately 2 hours and exhibits a linear increase in plasma concentrations for single doses from 0.5 mg up to 120 mg and multiple daily doses from 1 mg to 80 mg. 
Bazedoksifen se hitro absorbira s tmax približno 2 uri in kaže linearno zvišanje plazemskih koncentracij pri enkratnih odmerkih od 0,5 mg do 120 mg in večkratnih dnevnih odmerkih od 1 mg do 80 mg. Absolutna biološka uporabnost bazedoksifena je približno 6 %.
The safety of CONBRIZA has been evaluated in two multicentre, double-blind, randomised, placeboand active-control, Phase 3 trials: 7,492 evaluable postmenopausal women in a three-year osteoporosis treatment trial (1,886 women received bazedoxifene 20 mg; 1,872 women received bazedoxifene 40 mg; 1,849 women received raloxifene; 1,885 women received placebo) and 1,583 evaluable postmenopausal women in a 2-year osteoporosis prevention trial (321 women received bazedoxifene 10 mg; 322 women received bazedoxifene 20 mg; 319 women received bazedoxifene 40 mg; 311 women received raloxifene; 310 women received placebo). 
Varnost zdravila CONBRIZA so ovrednotili v dveh multicentričnih, dvojno slepih, randomiziranih, s placebom in zdravilno učinkovino nadzorovanih preskušanjih 3. faze: 7.492 žensk v postmenopavzi, ki jih je bilo mogoče ovrednotiti, v triletnem preskušanju zdravljenja osteoporoze (1.886 žensk je prejemalo bazedoksifen v odmerku 20 mg; 1.872 žensk je prejemalo bazedoksifen v odmerku 40 mg; 1.849 žensk je prejemalo raloksifen; 1.885 žensk je prejemalo placebo) in 1.583 žensk v postmenopavzi, ki jih je bilo mogoče ovrednotiti, v 2-letnem preskušanju preprečevanja osteoporoze (321 žensk je prejemalo bazedoksifen v odmerku 10 mg; 322 žensk je prejemalo bazedoksifen v odmerku 20 mg; 319 žensk je prejemalo bazedoksifen v odmerku 40 mg; 311 žensk je prejemalo raloksifen; 310 žensk je prejemalo placebo).
CONBRIZA 20 mg film-coated tablets Bazedoxifene 
CONBRIZA 20 mg filmsko obložene tablete bazedoksifen
Some patients have experienced the following side effects while taking CONBRIZA: 
Nekatere bolnice so med jemanjem zdravila CONBRIZA opazilenaslednje neželene učinke:
A total of 1,732 subjects continued into the second 2-year extension (bazedoxifene 20 mg: n=560, bazedoxifene 40/20 mg: n=582, and placebo: n=590). 
Skupno 1.732 oseb je nadaljevalo v drugo 2-letno podaljšanje (bazedoksifen 20 mg: n = 560, bazedoksifen 40/20 mg: n = 582, placebo n = 590).
Mean changes in mammographic breast density in the bazedoxifene 20 mg group were significantly reduced from baseline (-1.45 percentage points, p<0.05) while no changes were observed in the placebo group (-0.15 percentage points). 
Povprečne vrednosti sprememb mamografske gostote dojk v skupini, ki je prejemala bazedoksifen v odmerku 20 mg, so bile pomembno zmanjšane glede na izhodiščno vrednost (-1,45 odstotnih točk, p < 0,05), medtem ko v skupini, ki je prejemala placebo, niso opažali nobenih sprememb (-0,15 odstotnih točk).
The safety of CONBRIZA in patients with breast cancer has not been studied. 
Varnosti zdravila CONBRIZA pri bolnicah z rakom dojk niso proučevali.
In monkeys, treatment with bazedoxifene for 18 months resulted in the partial preservation of cortical and cancellous bone mass as determined by BMD measurements. 
Pri opicah je 18-mesečno dajanje bazedoksifena povzročilo delno ohranitev kortikalne in retikularne kostne mase, kar je bilo ugotovljeno z meritvami MKG.
Patients may experience visual symptoms such as visual acuity disturbance or blurred vision. 
Bolnice lahko doživijo motnje vida, kot so motena ostrina vida ali zamegljen vid.
Bazedoxifene caused corticomedullar nephrocalcinosis and enhanced spontaneous chronic progressive nephropathy (CPN) in male rats. 
Pri podganjih samcih je bazedoksifen povzročil kortikomedularno nefrokalcinozo in zvečal spontano kronično progresivno nefropatijo (CPN).
In 6-month carcinogenicity studies in transgenic mice, there was an increased incidence of benign, ovarian granulosa-cell tumours in female mice given 150 or 500 mg/kg/day. 
V 6-mesečnih študijah kancerogenosti na transgenskih miših se je zvečala pojavnost benignih ovarijskih granulozocelularnih tumorjev pri mišjih samicah, ki so prejemale po 150 ali 500 mg/kg/dan.
The prevention study (1,583 subjects; mean age, 58 years; mean years since menopause, 11) compared BMD effects of bazedoxifene (10, 20, or 40 mg daily), raloxifene (60 mg daily), and placebo. 
V študiji preprečevanja (1.583 oseb; povprečna starost 58 let; povprečno število let od menopavze 11) so primerjali učinke bazedoksifena (10, 20 ali 40 mg na dan), raloksifena (60 mg na dan) in placeba na MKG.
In a 2-year carcinogenicity study in rats, an increased incidence of benign, ovarian granulosa-cell tumours was observed in female rats at dietary concentrations of 0.03 and 0.1%. 
V dveletni študiji kancerogenosti na podganah so ugotovili zvečano pojavnost benignih ovarijskih granulozocelularnih tumorjev pri podganjih samicah pri koncentracijah v hrani 0,03 in 0,1 %.
How to take CONBRIZA 
Kako jemati zdravilo CONBRIZA
Bazedoxifene decreases bone resorption and reduces biochemical markers of bone turnover to the premenopausal range. 
Bazedoksifen zmanjšuje resorpcijo kosti in biokemijske markerje premene kostnine na razpon vrednosti, običajen pred menopavzo.
Limited clinical data (n=5) are available in subjects with moderate renal impairment (CrCl  50 ml/min). 
Pri bolnicah z zmerno okvaro ledvic (CrCl  50 ml/min) je na voljo malo kliničnih podatkov (n = 5).
If you have any further questions on the use or stopping the use of this medicine, ask your doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali farmacevtom.